BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16634536)

  • 21. The surgical management of rhinocerebral mucormycosis.
    Abu El-Naaj I; Leiser Y; Wolff A; Peled M
    J Craniomaxillofac Surg; 2013 Jun; 41(4):291-5. PubMed ID: 23058177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination antifungal therapy for invasive aspergillosis.
    Marr KA; Boeckh M; Carter RA; Kim HW; Corey L
    Clin Infect Dis; 2004 Sep; 39(6):797-802. PubMed ID: 15472810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacies and clinical roles of new antifungal agents].
    Tokimatsu I; Kadota J
    Nihon Ishinkin Gakkai Zasshi; 2006; 47(3):155-9. PubMed ID: 16940948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination antifungal therapy for invasive aspergillosis.
    Cesaro S; Visintin G
    Clin Infect Dis; 2005 Apr; 40(7):1073-5; author reply 1075-6. PubMed ID: 15825015
    [No Abstract]   [Full Text] [Related]  

  • 25. Successful treatment of invasive Aspergillus sinusitis with caspofungin and voriconazole.
    Chirch L; Roche P; Fuhrer J
    Ear Nose Throat J; 2008 Jan; 87(1):30-3. PubMed ID: 18357943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies.
    Steinbach WJ
    Curr Drug Targets Infect Disord; 2005 Sep; 5(3):203-10. PubMed ID: 16181140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.
    Kirkpatrick WR; Perea S; Coco BJ; Patterson TF
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2564-8. PubMed ID: 12121933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.
    MacCallum DM; Whyte JA; Odds FC
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3697-701. PubMed ID: 16127042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis.
    Chandrasekar PH; Cutright JL; Manavathu EK
    Clin Microbiol Infect; 2004 Oct; 10(10):925-8. PubMed ID: 15373889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis.
    van Vianen W; de Marie S; ten Kate MT; Mathot RA; Bakker-Woudenberg IA
    J Antimicrob Chemother; 2006 Apr; 57(4):732-40. PubMed ID: 16464895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes and factors affecting them in patients with rhino-orbito-cerebral mucormycosis.
    Kashkouli MB; Abdolalizadeh P; Oghazian M; Hadi Y; Karimi N; Ghazizadeh M
    Br J Ophthalmol; 2019 Oct; 103(10):1460-1465. PubMed ID: 30514712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of three patients with intracranially invasive sino-orbital aspergillosis.
    Yoon JS; Park HK; Cho NH; Lee SY
    Ophthalmic Plast Reconstr Surg; 2007; 23(5):400-6. PubMed ID: 17881994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful antifungal combination therapy with voriconazole and caspofungin.
    Schuster F; Moelter C; Schmid I; Graubner UB; Kammer B; Belohradsky BH; Führer M
    Pediatr Blood Cancer; 2005 Jun; 44(7):682-5. PubMed ID: 15700260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Sino-nasal endoscopic surgery in fungal sinusitis. Our experience].
    Alobid I; Bernal M; Menéndez LM; Alós L; Benítez P; Cardesa A; Mullol J
    Acta Otorrinolaringol Esp; 2002; 53(6):393-7. PubMed ID: 12402488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mediastinal mass due to Aspergillus fumigatus after lung transplantation: a case report.
    Shlobin OA; Dropulic LK; Orens JB; Mcdyer JF; Conte JV; Yang SY; Girgis R
    J Heart Lung Transplant; 2005 Nov; 24(11):1991-4. PubMed ID: 16297812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
    Almyroudis NG; Sutton DA; Fothergill AW; Rinaldi MG; Kusne S
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2587-90. PubMed ID: 17452481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful treatment of concomitant pulmonary zygomycosis and aspergillosis with a combination of amphotericin B lipid complex, caspofungin, and voriconazole in a patient on immunosuppression for chronic graft-versus-host disease.
    Verma A; Williams S; Trifilio S; Zembower T; Mehta J
    Bone Marrow Transplant; 2004 May; 33(10):1065-6. PubMed ID: 15048146
    [No Abstract]   [Full Text] [Related]  

  • 38. Diagnostic and therapeutic challenge of Aspergillus flavus scleritis.
    Fincher T; Fulcher SF
    Cornea; 2007 Jun; 26(5):618-20. PubMed ID: 17525663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disseminated invasive aspergillosis in a patient with acute leukaemia.
    Gottfredsson M; Steingrímsdóttir H
    Acta Biomed; 2006; 77 Suppl 2():10-3. PubMed ID: 16918060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of newer antifungal therapies in clinical practice: what do the data tell us?
    Perfect JR
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):15-23. PubMed ID: 15651178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.